Table 3.

Primary and secondary outcomes of patients

Endpoints	Medical strategy (n=38)	Interventional strategy (n=34)	Absolute difference, % (95% CI)	P value
30-day bleeding recurrence	17 (44.7)	4 (11.8)	33.0 (13.8 to 52.1)	0.002
90-day bleeding recurrence	18 (47.4)	5 (14.7)	32.7 (12.8 to 52.5)	0.003
In-hospital complications rate	0	4 (11.8)	11.8 (0.9 to 22.6)	0.045
90-day rate of rehospitalisation or invasive treatment for bleeding recurrence, n (%)*	9/35 (25.7)	2/32 (6.3)	19.5 (2.7 to 36.2)	0.032
Length of hospital stay (days)	4.0 (3.0–7.0)	4.0 (3.0–9.0)	–	0.75†
Mortality rate of 30 and 90 days‡	0	0	–	–

Data are n (%) or median (IQR 25%–75%).

*Analysis restricted to patients followed up to day 90. Bleeding recurrence status was missing at day 90 for four patients; invasive treatment was missing for one patient with bleeding recurrence during hospitalisation.

†Wilcoxon test.

‡Two patients in the medical strategy group were lost to follow-up at day 30 (at days 2 and 29, respectively); four other patients were lost to follow-up at day 90 (one patient in the medical strategy at day 74 and three patients in the interventional strategy at days 40, 48 and 67, respectively; see the online supplemental 2, e-Table 1). The mean/median duration of follow-up was 94.6±22.6 days/92 (90–99) days.